Vcanbio Cell & Gene Engineering Corp

Vcanbio Cell & Gene Engineering Corp CapEx/OCF

The CapEx to Operating Cash Flow Ratio of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Nov 18, 2026 is 15.80 %. In the previous year, CapEx to Operating Cash Flow Ratio was 23.60 % — a change of -33.05% (lower).

CapEx/OCF

15.80 %

YoY

-33.05%

Last updated:

CapEx to Operating Cash Flow Ratio of Vcanbio Cell & Gene Engineering Corp is 2025 15.80 % . CapEx to Operating Cash Flow Ratio of Vcanbio Cell & Gene Engineering Corp was 2024 23.60 % . It decreases by -33.05% lower compared to the previous year.

The Vcanbio Cell & Gene Engineering Corp CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2018
98.50 CNY
Jan 1, 2019
50.91 CNY
Jan 1, 2020
37.53 CNY
Jan 1, 2021
39.80 CNY
Jan 1, 2022
37.87 CNY
Jan 1, 2023
29.64 CNY
Jan 1, 2024
23.60 CNY
Jan 1, 2025
15.80 CNY
The Vcanbio Cell & Gene Engineering Corp CapEx/OCF history
YEARCapEx/OCFYoY
15.80 %-33.05%
23.60 %-20.35%
29.64 %-21.75%
37.87 %-4.84%
39.80 %+6.03%
37.53 %-26.28%
50.91 %-48.31%
98.50 %-16.62%
118.14 %-37.10%
187.83 %-88.07%
1,574.36 %+5,665.37%
27.31 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vcanbio Cell & Gene Engineering Corp Stock analysis

What does Vcanbio Cell & Gene Engineering Corp do? Vcanbio Cell & Gene Engineering Corp., Ltd. generates revenue through the development and sale of life sciences technology products. The company produces cytokines culture solutions, cosmetics, and detection reagents for domestic markets. Its business segments include cell culture, gene detection and storage, and the production of specialized biological products. The firm's domestic customers primarily purchase these products for research and commercial applications in the life sciences sector. Vcanbio focuses on cell culture and gene detection services, which are integral to its product offerings. The company's cytokines culture solutions are sold to domestic clients in the biotechnology and pharmaceutical industries. Detection reagents are also marketed to domestic laboratories and healthcare providers for diagnostic purposes. The firm leverages its 2,332 full-time employees to support research, development, and production activities. The company's product portfolio includes cosmetics alongside scientific reagents, targeting both consumer and professional markets. Domestic markets remain the primary focus for all sales, with no mention of international operations. Vcanbio's revenue streams are derived from the sale of its core products, which are developed and manufactured in-house. Vcanbio Cell & Gene Engineering Corp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock

CapEx to Operating Cash Flow Ratio of Vcanbio Cell & Gene Engineering Corp is 15.80 % in 2025.

CapEx to Operating Cash Flow Ratio of Vcanbio Cell & Gene Engineering Corp changed from 23.60 % to 15.80 %, representing a -33.05% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Vcanbio Cell & Gene Engineering Corp since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Vcanbio Cell & Gene Engineering Corp with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Vcanbio Cell & Gene Engineering Corp

All Key Metrics — Vcanbio Cell & Gene Engineering Corp